GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » PB Ratio

Terns Pharmaceuticals (Terns Pharmaceuticals) PB Ratio : 1.92 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), Terns Pharmaceuticals's share price is $6.11. Terns Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was $3.18. Hence, Terns Pharmaceuticals's PB Ratio of today is 1.92.

The historical rank and industry rank for Terns Pharmaceuticals's PB Ratio or its related term are showing as below:

TERN' s PB Ratio Range Over the Past 10 Years
Min: 0.25   Med: 1.13   Max: 2.71
Current: 1.55

During the past 6 years, Terns Pharmaceuticals's highest PB Ratio was 2.71. The lowest was 0.25. And the median was 1.13.

TERN's PB Ratio is ranked better than
69.97% of 1322 companies
in the Biotechnology industry
Industry Median: 2.54 vs TERN: 1.55

During the past 12 months, Terns Pharmaceuticals's average Book Value Per Share Growth Rate was -23.30% per year.

Back to Basics: PB Ratio


Terns Pharmaceuticals PB Ratio Historical Data

The historical data trend for Terns Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terns Pharmaceuticals PB Ratio Chart

Terns Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - - 1.11 1.97 1.64

Terns Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 1.95 1.20 1.64 -

Competitive Comparison of Terns Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Terns Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terns Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's PB Ratio falls into.



Terns Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Terns Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=6.11/3.182
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Terns Pharmaceuticals  (NAS:TERN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Terns Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Terns Pharmaceuticals (Terns Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Executives
Mark J. Vignola officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Seokho Bryan Yoon officer: COO and General Counsel NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram director, officer: Chief Executive Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Hongbo Lu director C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Lav Biosciences Fund V, L.p. 10 percent owner C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Lav Aqua Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Hopewell Resources Holdings Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Oriental Spring Venture Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Capital Gp Vii Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Asia Gp Iii, L.p. director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629

Terns Pharmaceuticals (Terns Pharmaceuticals) Headlines